TIM-3 Inhibitor - Pipeline Insight, 2024

This “TIM-3 Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TIM-3 Inhibitor Understanding

TIM-3 Inhibitor: Overview

T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immunoglobulin and mucin domain-containing cell surface molecule. The protein is characterized by a common structural organization consisting of an amino-terminal immunoglobulin variable domain (V domain) with five noncanonical cysteines, a mucin stalk, a transmembrane domain and a cytoplasmic tail. TIM-3 is known to interact with four ligands, galectin-9, phosphatidylserie (PtdSer), CEACAM-1and HMGB1 (high mobility group box-1). Tim-3 is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Various preclinical data support the therapeutic modulation of TIM3 in multiple disease contexts including autoimmunity, infection, and cancer. The blocking of Tim-3 and PD-1 together can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIM-3 Inhibitor R&D. The therapies under development are focused on novel approaches for TIM-3 Inhibitor.

TIM-3 Inhibitor Emerging Drugs Chapters

This segment of the TIM-3 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIM-3 Inhibitor Emerging Drugs

Cobolimab: Glaxo SmithKlineCobolimab is a novel IgG4 anti-TIM-3 monoclonal antibody. It is under clinical investigation in clinical trial in combination with Dostarlimab and Docetaxel in Advanced Non-small cell lung cancer (NSCLC). By binding to and blocking TIM-3, Cobolimab allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce theirgrowth.

BMS-986258: Bristol-Myers Squibb BMS-986258 (anti-TIM-3) is a fully-human monoclonal antibody targeting TIM-3 (T cell immunoglobulin and mucin domain-3). It is the first clinical candidate from the discovery collaboration between Five Prime Therapeutics and BMS that includes targets in three immune checkpointpathways.

TIM-3 Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different TIM-3 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TIM-3 Inhibitor

There are approx. 15+ key companies which are developing the TIM-3 Inhibitor. The companies which have their TIM-3 Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Novarits Oncology.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

TIM-3 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIM-3 Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIM-3 Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIM-3 Inhibitor drugs.

TIM-3 Inhibitor Report Insights

• TIM-3 Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TIM-3 Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing TIM-3 Inhibitor drugs?
• How many TIM-3 Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for TIM-3 Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TIM-3 Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TIM-3 Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novarits
• GlaxoSmithKline
• Roche
• Incyte Corporation
• Bristol-Myers Squibb
• Novartis
• Interprotein
• TrueBinding
• Celgene
• Sutro Biopharma
• Neologics Bioscience
• Symphogen

Key Products

• Sabatolimab
• Cobolimab
• RG-7769
• INCAGN 02390
• BMS 986258
• MAS-825

Research program: anticancer peptide therapeutics- Anti-T-cell immunoglobulin and mucin domain-3 monoclonal antibody
Research program: antibody based therapeutics- NB 002

• Sym-023

This product will be delivered within 2 business days.